Sage Defies Adversity on Its Way Up

This commentary was originally sent to Trifecta Stocks subscribers at 04:30 on April 10.

The biotech group has been a mixed bag of late. Chief among concerns is the issue of how new policy is going to affect pricing.

Yet, some names have defied the rhetoric and hyperbole and just continue to move upwards. Sage Therapeutics  (SAGE) is one of those names.

The stock just hit a new high last week on good volume. Earlier in the week, the stock gapped modestly higher and continues to hold that gap, which is bullish.

Momentum indicators are on a buy signal, as is the moving average convergence divergence (MACD).

Most important is the persistency in "buying the dips" -- a sign institutions continue to climb onboard the n
Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.